<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386709</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A000357-40</org_study_id>
    <nct_id>NCT02386709</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer</brief_title>
  <acronym>TREN</acronym>
  <official_title>Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Treatment in Patients With Mammary Gland Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <brief_summary>
    <textblock>
      Neoadjuvant chemotherapy is frequently proposed to patients with mammary gland cancer. The&#xD;
      aim is to reduce tumor volume before surgical therapy. Obtaining a pathologic Complete&#xD;
      Response (pCR) is regarded as a good prognostic factor with less risk of recurrence. The rate&#xD;
      of pCR is about 20%, although there are important variations according to tumor subtype and&#xD;
      the type of treatment. The objective of the new therapeutic strategies is to increase this&#xD;
      response rate.&#xD;
&#xD;
      The purpose of this study is to investigate the possibility of early evaluation of&#xD;
      neoadjuvant chemotherapy response after one cycle of neoadjuvant chemotherapy by positron&#xD;
      emission tomography (PET) with (18) F-fluorodeoxyglucose (FDG) in patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2015</start_date>
  <completion_date type="Anticipated">March 25, 2028</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference of Δ SUV (Standardised Uptak Value) between 18F-FDG PET 1 and 18F-FDG PET2 to predict pCR during neoadjuvant chemotherapy</measure>
    <time_frame>early metabolic response mesure by 18F-FDG PET (difference of Δ SUV) at 3 weeks after neoadjuvant chemotherapy to predict pathologic Complete Response (pCR) by exploiting PET data realized before treatment (PET1) and after a cure of chemothrapy (PET2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Δ SUV (Standardised Uptak Value) threshold at 3 weeks</measure>
    <time_frame>Δ SUV threshold at 3 weeks allowing to show the absence of response to treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>relation between early metabolic response (difference of Δ SUV ) assessed by 18F-FDG PET at 3 weeks and Progression-free survival</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modification of tumor perfusion by 18F-FDG PET</measure>
    <time_frame>modifications of tumor perfusion befoire and after one cycle(3 weeks) neoadjuvant chemotherapy by exploiting PET/PDG data (PET1 and PET2)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">275</enrollment>
  <condition>FDG PET</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnostic&#xD;
PET1 : before the neoadjuvant treatment&#xD;
start neoadjuvant treatment&#xD;
PET2: two weeks after the start of the first course of chemotherapy&#xD;
surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FDG PET</intervention_name>
    <description>FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient having been informed of the study&#xD;
&#xD;
          -  patient affiliated to a social health insurance&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  patient presenting a breast cancer histologically confirmed&#xD;
&#xD;
          -  indication of neoadjuvant chemotherapy treatment (classification UICC: II or III)&#xD;
&#xD;
          -  patient agrees with exploitation of his clinical, biological and image data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distant metastasis&#xD;
&#xD;
          -  contraindications to chemotherapy&#xD;
&#xD;
          -  contraindications to surgery&#xD;
&#xD;
          -  refusal&#xD;
&#xD;
          -  serious illness not balanced, subjacent infection&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  diabetes not controlled (glycemia&gt; 8 mmol/L)&#xD;
&#xD;
          -  psychiatric disease&#xD;
&#xD;
          -  patient under supervision, trusteeship or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre COCHET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Feores François Lelcerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie REDERSTORFF, PhD</last_name>
    <phone>0033 3 80 73 75 00</phone>
    <phone_ext>3461</phone_ext>
    <email>ERederstorff@cgfl.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandrine TIAGO</last_name>
    <email>stiago@cgfl.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Emilie REDERSTORFF</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie REDERSTORFF, PhD</last_name>
      <phone>0033 3 80 73 75 00</phone>
      <phone_ext>3461</phone_ext>
      <email>ERederstorff@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sandrine TIAGO</last_name>
      <phone>0033 3 80 73 75 00</phone>
      <email>stiago@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandre COCHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2015</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

